The Food and Drug Administration's recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw that the drug had prolonged the lives of a third of the participants in a clinical trial. "It was devastating news," said Trisha Wise-Draper, a dermatologist at the University of Cincinnati who had patients enrolled in the trial. "This is life or death for maybe 2,000 patients," added Eric Whitman, medical director of the